Fisher Asset Management LLC Has $18.55 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Fisher Asset Management LLC boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.8% in the third quarter, Holdings Channel.com reports. The firm owned 324,005 shares of the biopharmaceutical company’s stock after purchasing an additional 20,721 shares during the quarter. Fisher Asset Management LLC’s holdings in Halozyme Therapeutics were worth $18,546,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Janus Henderson Group PLC raised its holdings in Halozyme Therapeutics by 24.0% in the 1st quarter. Janus Henderson Group PLC now owns 531,125 shares of the biopharmaceutical company’s stock valued at $21,604,000 after buying an additional 102,911 shares during the last quarter. Swedbank AB bought a new position in shares of Halozyme Therapeutics during the first quarter valued at $13,927,000. Verity Asset Management Inc. lifted its holdings in shares of Halozyme Therapeutics by 36.5% during the first quarter. Verity Asset Management Inc. now owns 39,089 shares of the biopharmaceutical company’s stock worth $1,590,000 after purchasing an additional 10,461 shares during the period. Boston Partners grew its stake in shares of Halozyme Therapeutics by 14.1% in the first quarter. Boston Partners now owns 630,368 shares of the biopharmaceutical company’s stock worth $25,500,000 after purchasing an additional 77,976 shares during the last quarter. Finally, Aurora Investment Counsel increased its holdings in Halozyme Therapeutics by 21.0% in the first quarter. Aurora Investment Counsel now owns 44,949 shares of the biopharmaceutical company’s stock valued at $1,829,000 after purchasing an additional 7,793 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $40,063,244.80. This trade represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 60,000 shares of company stock valued at $3,425,000 in the last three months. Corporate insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $48.47 on Thursday. The firm has a market capitalization of $6.17 billion, a P/E ratio of 15.82, a P/E/G ratio of 0.43 and a beta of 1.29. The firm’s 50-day moving average price is $54.00 and its 200-day moving average price is $53.71. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53.

Analyst Ratings Changes

HALO has been the topic of several recent research reports. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Piper Sandler upped their target price on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a report on Monday, November 4th. JMP Securities increased their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Morgan Stanley boosted their price target on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, Wells Fargo & Company cut shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.